Gen-Probe Life Sciences Ltd. has completed the consolidation of its Molecular Genetic Services (MGS) business at its newly expanded facilities in Manchester.
Gen-Probe Incorporated has expanded its footprint in Wythenshawe, Manchester from 11,000 sq ft to 67,000 sq ft. Among other benefits, the expansion of the facility will provide the catalyst for theconsolidation and further development of a suite of outsourced genomic services. Gen-Probe Life Sciences Ltd. will further develop its suite of genomic services aimed specifically at the R&D stage of drug development. These services will provide support to translational research through the discovery, qualification, and validation of biomarkers and IUO assays with the potential for both drug development and companion diagnostic applications.
David Scott, Senior Director, commercial services and Diaclone, said, “We are excited to beimplementing this next stage in the strategic development of our pharma services brand. We believe that the potential to identify and develop both genomic and proteomic assays for biomarkers at an early stage presents a real value proposition to biopharmaceutical companies seeking companion diagnostics.”
As part of this consolidation, Gen-Probe Life Sciences Ltd. has appointed Dr. Bob Holt as MGS manager responsible for the growth and development of the MGS business, and Haroon Allybacus as business development manager for its pre-clinical, clinical, and cGMP drug development services.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.